WO1995001155A1 - Oral compositions - Google Patents
Oral compositions Download PDFInfo
- Publication number
- WO1995001155A1 WO1995001155A1 PCT/EP1994/002132 EP9402132W WO9501155A1 WO 1995001155 A1 WO1995001155 A1 WO 1995001155A1 EP 9402132 W EP9402132 W EP 9402132W WO 9501155 A1 WO9501155 A1 WO 9501155A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- surfactant
- nonionic surfactant
- ethylene oxide
- sanguis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/90—Block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to oral compositions which comprise antibodies.
- the present invention relates to oral compositions which comprise antibodies, the shelf life of which is improved by the inclusion in the oral composition of a certain class of surfactants.
- compositions in the context of the present invention are " compositions for the care of the human teeth and mouth, and comprise compositions such as dentifrices, toothpastes, gels, mouthwashes, powders, tablets, lozenges, gargle solutions and the like.
- Antibodies in the context of the present invention include polyclonal antibodies, monoclonal antibodies, antibody fragments binding to immobilised antigens, as well as antibody or antibody fragment-containing systems as described in our EP-A-450,800, 451,972 and 453,097.
- Oral care compositions frequently contain a surfactant, and the most common class of surfactants used in oral care compositions is the class of anionic surfactants.
- the most frequently used surfactant of this class is sodium laurylsulphate.
- this surfactant is rather incompatible with antibodies because it impairs their efficacy and shelf-life in the compositions.
- the present invention relates to an oral care composition which comprises an antibody and a surfactant, and is characterised in that the surfactant is or comprises a nonionic surfactant.
- the invention also relates to the use of a nonionic surfactant as stabilizing agent in antibody-containing oral care compositions.
- An essential element of the present invention is the presence in the composition of a nonionic surfactant.
- the nonionic surfactant is basically a condensation product of alkylene oxides with a hydrophobic moiety which can be a fatty alcohol, a fatty acid, fatty acid amide, a fatty acid ester, an alkylphenol and so on.
- Typical examples are the condensation products of ethylene oxide, propylene oxide, butylene oxide and mixtures thereof with C 8 -C 18 primary or secondary, branched or straight- chain alcohols, C 8 -C 18 fatty acid amides, C 9 -C 18 alkylphenols, and block copolymers of ethyleneoxide " and propyleneoxide. Further suitable examples can be found in M. Schick, "Nonionic Surfactants” 1967. Naturally, the nonionic surfactant should be suitable for use in oral products, and should meet the safety requirements for such use. Particularly suitable examples are the ethylene oxide/propylene oxide block copolymers of the general formula
- a and b are integers greater than 0 which are commercially available from ICI under the trade name "Synperonic PE” or "Pluronic".
- Synperonic PE or "Pluronic”.
- Such products have an approximate molecular weight ranging from abt. 4,000 to abt. 15,000, and have an HLB ranging from 27-30.5.
- Specific examples of these preferred products are Synperonic PE/F38, PE/F68, PE/F88 and PE/F108.
- nonionic surfactants is the class of alkoxylated fatty acid esters such as hydrogenated castor oil, condensed with ethylene oxide, e.g. hydrogenated castor oil, condensed with 40 or 60 moles of ethylene oxide, commercially available from BASF under the trade name Cremophor RH40 and RH60.
- suitable examples of nonionic surfactants include polyoxyethylene sorbitan monolaurate and polyoxyethylene sorbitan monooleate, known as Tween 20 and Tween 80, available from ICI. Mixtures of various nonionic surfactants may also be used.
- the nonionic surfactant is used in the present invention in an amount of 0.01-6%, usually 0.1-3% and preferably 0.25-2% by weight.
- antibodies which are used in the present invention include antibodies against S.sancmis or ag ' ainst glucose oxidase or against a peroxidase enzyme such as horse radish peroxidase, or against glucosyltransferase; antibody fragments e.g. against lysozyme or against S.sancmis or against a protease.
- assembly and target bound conjugated complexes (DACC) and self assembling complexes (DESC) as described in our EP-A- 450,800, 451,972 and 453,097 may be used.
- the antibodies are used in the present invention in a therapeutically effective amount. This may vary depending upon their therapeutic effect and their purity, and in general ranges from 0.01 microgra me per gramme of the composition to 100 milligramme per gramme of the composition. Usually, the amount will be between 0.3 microgramme to 10 milligramme, and for most practical purposes from 10 microgramme to 1 milligramme. Naturally, mixtures of various antibodies may also be used.
- the oral care compositions of the present invention may furthermore comprise optional, conventional ingredients such as pharmaceutically acceptable carriers like starch, sucrose, water or water/alcohol systems etc..
- optional, conventional ingredients such as pharmaceutically acceptable carriers like starch, sucrose, water or water/alcohol systems etc.
- Small amounts of surfactants which are compatible with the nonionic surfactants may also be included, such as amphoteric and cationic surfactants.
- such formulation When formulated into a dentifrice, such formulation may contain all the usual dentifrice ingredients.
- they may comprise particulate abrasive materials such as silicas, aluminas, calcium carbonates, dicalciumphosphates, hydroxyapatites, trimetaphosphates, insoluble hexametaphosphates and so on, usually in amounts between 5 and 60% by weight.
- the dentifrice formulations may comprise humectants such as glycerol, sorbitol, propyleneglycol, xylitol, lactitol and so on.
- Binders and thickeners such as sodium carboxymethyl- cellulose, xanthan gum, gum arabic etc. may also be included, as well as synthetic polymers such as polyacrylates and carboxyvinyl polymers such as Carbopol®.
- Flavours such as peppermint and spearmint oils may also be included, as well as preservatives, opacifying agents, colouring agents, pH-adjusting agents, sweetening agents and so on.
- Anti-bacterial agents may also be included such as Triclosan, chlorhexidine, copper-, zinc- and stannous salts such as zinc citrate, sodium zinc citrate and stannous pyrophosphate, sanguinarine extract, metronidazole.
- Further examples of anti-bacterial agents are quaternary ammonium compounds such as cetylpyridinium chloride; bis-guanides such as chlorhexidine digluconate, hexetidine, octenidine, alexidine; halogenated bisphenolic compounds such as 2,2' methylenebis-(4-chloro-6-bromophenol) .
- Polymeric compounds which can enhance the delivery of active ingredients such as anti-bacterial agents can also be included.
- examples of such polymers are copolymers of polyvinylmethylether with maleic anhydride and other similar delivery enhancing polymers, e.g. those described in DE-A-3,942,643 (Colgate)
- anti-inflammatory agents such as ibuprofen, flurbiprofen, aspirin, indomethacin etc. may also be included.
- Anti-caries agents such as sodium- and stannous fluoride, aminefluorides, monosodiumfluorophosphate, casein, plaque buffers such as urea, calcium lactate, calcium glycerophosphate, strontium polyacrylates may also be included.
- Other optional ingredients include vitamins such as Vitamin C, plant extracts, potassium salts such as potassium citrate, potassium chloride, potassium sulphate, potassium tartrate and potassium nitrate.
- Buffers and salts to buffer the pH and ionic strength of the compositions may also be included. Liposomes and other encapsulates may also be used to improve delivery or stability.
- the oral compositions may comprise anti- calculus agents such as alkalimetalpyrophosphates, hypophosphite-containing polymers, organic phosphonates, phosphocitrates etc..
- anti- calculus agents such as alkalimetalpyrophosphates, hypophosphite-containing polymers, organic phosphonates, phosphocitrates etc.
- bleaching agents such as peroxy compounds e.g. potassiumperoxydiphosphate, effervescing systems such as sodiumbicarbonate/citric acid systems, colour change systems, and so on.
- bacteriophages bacteriophages
- enzymes bioactive peptides
- anti-bacterial adhesion polymers bacteriophages, enzymes, bioactive peptides and anti-bacterial adhesion polymers.
- the oral care composition When formulated as a mouthwash, the oral care composition usually comprises a water/alcohol solution, flavour, humectant, sweetener and colorant.
- the present invention will further be illustrated by way of Example.
- HRP horse radish peroxidase
- GOx anti-bovine glucose oxidase conjugate
- Cappel anti-bovine glucose oxidase
- S.sanguis cell suspension enzyme immunoassays were performed in which varying concentrations of nonionic surfactant (in the range 0.05%-10% w/v) were added to antibody containing solutions and wash solutions, before mixing with target S.sanguis cells.
- concentrations of nonionic surfactant in the range 0.05%-10% w/v
- Nonionic-surfactant concentrations of up to 10% w/v did not interfere with antibody/antigen interactions as measured in this immunoassay system.
- Nonionic-surfactant concentrations in the range 0.001%-10% w/v appeared to significantly enhance the enzyme activity measured.
- nonionic surfactants tested were Synperonic PE/F68 and Cremophor RH40.
- anionic surfactant sodium dodecylsulphate was also tested.
- a second enzyme immunocomplex was used to investigate the effect of Synperonic PE/F68 and Cremphore RH40 upon monoclonal antibodies.
- the integrity of the complex-below depends upon a greater number of antibody/antigen interactions than that of Example 1. Both anti-enzyme antibodies are murine monoclonals.
- Reagents were added in two steps, as in the previous example, with initial exposure of S.sanguis cells in suspension to the primary polyclonal mouse anti-S.sanguis antibody (1/100 final dilution) , followed by simultaneous exposure to the remaining reagents.
- the two incubation steps were interspersed with buffer washes and followed by substrate addition as described in Example 1.
- Nonionic surfactant concentrations up to 10% w/v did not interfere with antibody/antigen interactions as measured in this immunoassay system.
- Cremophor RH40 and Synperonic PE/F68 upon binding of anti-lysozyme Fv immunoglobulin fragment (prepared by genetic engineering techniques) to lysozyme was investigated using the standard assay system shown below:
- Anti-lysozyme Fv fragment, rabbit anti-mouse Fv and commercial goat anti-rabbit alkaline phosphatase conjugate were added sequentially to lysozyme immobilized on the surface of a nylon peg. In each case 60 minute incubations at 37°C were followed by buffer washes to remove unbound reagents. Finally para-nitrophenolphosphate enzyme substrate solution was added and generation of the yellow product was measured by spectrophotometry (OD 405 ) . No adverse effect upon fragment binding was observed at a nonionic surfactant concentration up to 10% w/v.
- the standard assay format shown below has been developed to evaluate the resistance of an immunoglobulin, pre-bound to the corresponding antigen, to surfactant induced denaturation or deformation.
- the relative resistance of polyclonal and monoclonal mouse anti-S.sanguis antibodies were measured.
- Antibody reagents were added sequentially to whole S.sanguis cells immobilized on plastic microtitre dishes, with intermediate wash steps to remove unbound antibody. Varying concentrations of nonionic surfactant or sodium dodecyl -sulphate (SDS) were added to wells containing bound anti-S.sanguis antibody and incubated for 20 minutes at approximately 20°C. After further washing, anti-mouse immunoglobulin-alkaline phosphatase conjugate was added to detect bound antibody.
- SDS sodium dodecyl -sulphate
- Nonionic surfactants at concentrations up to 1% (w/v) did not reverse the binding of murine monoclonal antibodies to S.sanguis cells, even though the same antibodies were dramatically affected by exposure to SDS at > 0.2% w/v.
- Polyclonal anti-S.sanguis antibodies tested behaved similarly, although greater resistance to the chaotropic ' effects of SDS was observed as compared with the monoclonals.
- Immunoreactivity of whole antibody against glucose oxidase was measured by enzyme linked immunosorbent assay (ELISA) in which glucose oxidase was immobilized on the surface of a nylon peg. The pegs were exposed sequentially to test paste samples containing anti-glucose oxidase .antibody, anti-mouse alkaline phosphatase enzyme immuno-conjugate, and finally to enzyme substrate, para-nitrophenylphosphate. The generation of yellow product was measured by spectrophotometry (O.D. 405 nm) .
- anti-GOx glucose oxidase
- PBS phosphate buffered saline
- the composition of PBS 8.5 g/1 NaCl + 1.07 g/1 Na 2 HP0 4 (anhydrous) + 0.39 g/1 NaH 2 P0 4 .2H 2 0.
- the solution was filter sterilised through a 0.22 ⁇ m Millipore filter prior to storage.
- the anti-GOx was added at 60 ⁇ g/ml.
- the solution was stored at 28°C. The residual immunoreactivity was measured with time. Storage of anti-GOx in buffer:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to an oral care composition comprising an antibody and a surfactant. According to the invention, the surfactant is a nonionic surfactant, which provides for improved compatibility with the antibody and enhances its immunoreactivity on storage and its antibody binding and/or enzyme activity. Specific nonionic surfactants are particular ethylene oxide/propylene oxide block copolymers and ethoxylated hydrogenated castor oil.
Description
"Oral Compositions"
The present invention relates to oral compositions which comprise antibodies.
More particularly, the present invention relates to oral compositions which comprise antibodies, the shelf life of which is improved by the inclusion in the oral composition of a certain class of surfactants.
Oral compositions in the context of the present invention are" compositions for the care of the human teeth and mouth, and comprise compositions such as dentifrices, toothpastes, gels, mouthwashes, powders, tablets, lozenges, gargle solutions and the like.
Antibodies in the context of the present invention include polyclonal antibodies, monoclonal antibodies, antibody fragments binding to immobilised antigens, as well as antibody or antibody fragment-containing systems as described in our EP-A-450,800, 451,972 and 453,097.
Oral care compositions frequently contain a surfactant, and the most common class of surfactants used in oral care compositions is the class of anionic surfactants. The most frequently used surfactant of this class is sodium laurylsulphate. However, we have found that this surfactant is rather incompatible with antibodies because it impairs their efficacy and shelf-life in the compositions.
We have now found that this disadvantage can be overcome to a significant extent by using a nonionic surfactant instead of an anionic surfactant. We have found that this class of nonionic surfactants combines good compatibility with the antibodies, providing improved immunoreactivity on longer
term storage and enhancing antibody binding and/or enzyme activity.
Consequently, in its broadest aspect the present invention relates to an oral care composition which comprises an antibody and a surfactant, and is characterised in that the surfactant is or comprises a nonionic surfactant.
The invention also relates to the use of a nonionic surfactant as stabilizing agent in antibody-containing oral care compositions.
An essential element of the present invention is the presence in the composition of a nonionic surfactant. The nonionic surfactant is basically a condensation product of alkylene oxides with a hydrophobic moiety which can be a fatty alcohol, a fatty acid, fatty acid amide, a fatty acid ester, an alkylphenol and so on.
Typical examples are the condensation products of ethylene oxide, propylene oxide, butylene oxide and mixtures thereof with C8-C18 primary or secondary, branched or straight- chain alcohols, C8-C18 fatty acid amides, C9-C18 alkylphenols, and block copolymers of ethyleneoxide"and propyleneoxide. Further suitable examples can be found in M. Schick, "Nonionic Surfactants" 1967. Naturally, the nonionic surfactant should be suitable for use in oral products, and should meet the safety requirements for such use. Particularly suitable examples are the ethylene oxide/propylene oxide block copolymers of the general formula
H-(0-CH2CH2)a-(O-CH(CH3)CH2)b-(0-CH2CH2)a-0H
in which a and b are integers greater than 0 which are commercially available from ICI under the trade name "Synperonic PE" or "Pluronic". Of these block
copolymers particularly those, containing 80% by weight of ethylene oxide in the molecule are preferred. Such products have an approximate molecular weight ranging from abt. 4,000 to abt. 15,000, and have an HLB ranging from 27-30.5. Specific examples of these preferred products are Synperonic PE/F38, PE/F68, PE/F88 and PE/F108.
Another type of preferred nonionic surfactants is the class of alkoxylated fatty acid esters such as hydrogenated castor oil, condensed with ethylene oxide, e.g. hydrogenated castor oil, condensed with 40 or 60 moles of ethylene oxide, commercially available from BASF under the trade name Cremophor RH40 and RH60. Other suitable examples of nonionic surfactants include polyoxyethylene sorbitan monolaurate and polyoxyethylene sorbitan monooleate, known as Tween 20 and Tween 80, available from ICI. Mixtures of various nonionic surfactants may also be used.
The nonionic surfactant is used in the present invention in an amount of 0.01-6%, usually 0.1-3% and preferably 0.25-2% by weight.
Examples of antibodies which are used in the present invention include antibodies against S.sancmis or ag'ainst glucose oxidase or against a peroxidase enzyme such as horse radish peroxidase, or against glucosyltransferase; antibody fragments e.g. against lysozyme or against S.sancmis or against a protease. Furthermore, assembly and target bound conjugated complexes (DACC) and self assembling complexes (DESC) as described in our EP-A- 450,800, 451,972 and 453,097 may be used.
The antibodies are used in the present invention in a therapeutically effective amount. This may vary depending upon their therapeutic effect and their purity, and in general ranges from 0.01 microgra me per gramme of the composition to 100 milligramme per gramme of the
composition. Usually, the amount will be between 0.3 microgramme to 10 milligramme, and for most practical purposes from 10 microgramme to 1 milligramme. Naturally, mixtures of various antibodies may also be used.
The oral care compositions of the present invention may furthermore comprise optional, conventional ingredients such as pharmaceutically acceptable carriers like starch, sucrose, water or water/alcohol systems etc.. Small amounts of surfactants which are compatible with the nonionic surfactants may also be included, such as amphoteric and cationic surfactants. When formulated into a dentifrice, such formulation may contain all the usual dentifrice ingredients. Thus, they may comprise particulate abrasive materials such as silicas, aluminas, calcium carbonates, dicalciumphosphates, hydroxyapatites, trimetaphosphates, insoluble hexametaphosphates and so on, usually in amounts between 5 and 60% by weight.
Furthermore, the dentifrice formulations may comprise humectants such as glycerol, sorbitol, propyleneglycol, xylitol, lactitol and so on.
Binders and thickeners such as sodium carboxymethyl- cellulose, xanthan gum, gum arabic etc. may also be included, as well as synthetic polymers such as polyacrylates and carboxyvinyl polymers such as Carbopol®.
Flavours such as peppermint and spearmint oils may also be included, as well as preservatives, opacifying agents, colouring agents, pH-adjusting agents, sweetening agents and so on.
Anti-bacterial agents may also be included such as Triclosan, chlorhexidine, copper-, zinc- and stannous salts such as zinc citrate, sodium zinc citrate and stannous pyrophosphate, sanguinarine extract, metronidazole. Further
examples of anti-bacterial agents are quaternary ammonium compounds such as cetylpyridinium chloride; bis-guanides such as chlorhexidine digluconate, hexetidine, octenidine, alexidine; halogenated bisphenolic compounds such as 2,2' methylenebis-(4-chloro-6-bromophenol) .
Polymeric compounds which can enhance the delivery of active ingredients such as anti-bacterial agents can also be included. Examples of such polymers are copolymers of polyvinylmethylether with maleic anhydride and other similar delivery enhancing polymers, e.g. those described in DE-A-3,942,643 (Colgate)
Furthermore anti-inflammatory agents such as ibuprofen, flurbiprofen, aspirin, indomethacin etc. may also be included.
Anti-caries agents such as sodium- and stannous fluoride, aminefluorides, monosodiumfluorophosphate, casein, plaque buffers such as urea, calcium lactate, calcium glycerophosphate, strontium polyacrylates may also be included. Other optional ingredients include vitamins such as Vitamin C, plant extracts, potassium salts such as potassium citrate, potassium chloride, potassium sulphate, potassium tartrate and potassium nitrate.
Buffers and salts to buffer the pH and ionic strength of the compositions may also be included. Liposomes and other encapsulates may also be used to improve delivery or stability.
Furthermore, the oral compositions may comprise anti- calculus agents such as alkalimetalpyrophosphates, hypophosphite-containing polymers, organic phosphonates, phosphocitrates etc..
Other optional ingredients that may be included are e.g.
bleaching agents such as peroxy compounds e.g. potassiumperoxydiphosphate, effervescing systems such as sodiumbicarbonate/citric acid systems, colour change systems, and so on.
Other optional ingredients are bacteriophages, enzymes, bioactive peptides and anti-bacterial adhesion polymers.
When formulated as a mouthwash, the oral care composition usually comprises a water/alcohol solution, flavour, humectant, sweetener and colorant.
The present invention will further be illustrated by way of Example.
EXAMPLE 1
The effect of Synperonic PE/F68 and Cre ophor RH40 on the binding of a polyclonal antibody to its antigen was examined using the standard enzyme immuno assay system shown below:
See fig. 1
To a washed suspension of S.sanguis cells was added anti- S.sanguis bovine hyper-immune serum (1/100 final dilution in phosphate buffered saline (PBS) ) . Following 30 minutes incubation at approximately 20°C, any remaining unbound anti-S.sanguis antibody was removed by centrifugation of S.sanguis cells, followed by resuspension in PBS, repeated three times. Commercial anti-bovine horse radish peroxidase (HRP) conjugate (Zymed) and anti-bovine glucose oxidase
(GOx) conjugate (Cappel) were added simultaneously to suspended target cells (both at a final dilution of 1/100 in PBS) , with incubation and subsequent wash steps as before. The presence of bound GOx and HRP on the bacterial cell surface was then detected using enzyme substrate containing glucose and tetramethylbenzidine; the combined activity of GOx and HRP resulting in formation of a blue product measurable by spectrophotometry. A control preparation was included in which the first antibody (anti- S.sanguis. was omitted, to confirm that subsequent enzyme- immunoconjugate binding was specific.
A number of S.sanguis cell suspension enzyme immunoassays were performed in which varying concentrations of nonionic surfactant (in the range 0.05%-10% w/v) were added to antibody containing solutions and wash solutions, before mixing with target S.sanguis cells. The effect of the nonionic surfactant at each concentration upon the levels of bound GOx and HRP activity, and consequently upon the efficiency of antibody/antigen binding interactions at each stage of the assay was measured as a function of product formation (OD450) .
Nonionic-surfactant concentrations of up to 10% w/v did not interfere with antibody/antigen interactions as measured in this immunoassay system. Nonionic-surfactant concentrations in the range 0.001%-10% w/v appeared to significantly enhance the enzyme activity measured.
The nonionic surfactants tested were Synperonic PE/F68 and Cremophor RH40. For comparison an anionic surfactant, sodium dodecylsulphate was also tested.
Detergent O.D. 450 nm Concentration % (w/v) Synperonic Cremophor SDS
10 1.928 1.212 0.006
5 1.974 1.132 0.004
2 1.609 1.097 0.009
1 1.484 1.014 0.026
0.5 1.306 0.944 0.021
0.2 1.162 1.049 0.049
0.1 1.122 0.821 0.132 _-
0.06 1.013
0.05 0.938 0.162
0.015 0.84
0.001 0.835 0.84
EXAMPLE 2
A second enzyme immunocomplex was used to investigate the effect of Synperonic PE/F68 and Cremphore RH40 upon monoclonal antibodies. The integrity of the complex-below depends upon a greater number of antibody/antigen interactions than that of Example 1. Both anti-enzyme antibodies are murine monoclonals.
See fig. 2
Reagents were added in two steps, as in the previous example, with initial exposure of S.sanguis cells in suspension to the primary polyclonal mouse anti-S.sanguis antibody (1/100 final dilution) , followed by simultaneous exposure to the remaining reagents. The two incubation
steps were interspersed with buffer washes and followed by substrate addition as described in Example 1.
Nonionic surfactant concentrations up to 10% w/v did not interfere with antibody/antigen interactions as measured in this immunoassay system.
Detergent O.D. 450 nm Concentration % (w/v) Synperonic Cremophor SDS
10 1.01 0.888 0,002
5 0.832 1.323 0
2 0.789 1.032 0
1 0.806 0.911 0
0.5 0.827 0.683 0
0.2 0.704 1.136 0
0.1 0.644 0.507 0.159
0.05 0.659 0.659 0.985
0.001 1.16 1.163 1.165
EXAMPLE 3
The effect of Cremophor RH40 and Synperonic PE/F68 upon binding of anti-lysozyme Fv immunoglobulin fragment (prepared by genetic engineering techniques) to lysozyme was investigated using the standard assay system shown below:
See fig. 3
Anti-lysozyme Fv fragment, rabbit anti-mouse Fv and commercial goat anti-rabbit alkaline phosphatase conjugate
were added sequentially to lysozyme immobilized on the surface of a nylon peg. In each case 60 minute incubations at 37°C were followed by buffer washes to remove unbound reagents. Finally para-nitrophenolphosphate enzyme substrate solution was added and generation of the yellow product was measured by spectrophotometry (OD405) . No adverse effect upon fragment binding was observed at a nonionic surfactant concentration up to 10% w/v.
Nonionic surfactant concentrations in the range of 0.02%- 10% w/v appeared to significantly enhance the enzyme activity measured.
Detergent O.D. 450 nm Concentration % (w/v) Cremophor Synperonic SDS
10 0.826 1.05 0.047
5 0.834 0.981 0.048
2 0.82 0.903 0.052
1 0.823 0.881 0.062
0.5 0.787 0.92 0.073
0.2 0.787 0.929 0.375
0.1 0.76 0.965 0.627
0.05 0.778 0.924 0.635 '
0.02 0.764 0.894 0.603
0.001 0.642 0.641 0.642
EXAMPLE 4
The standard assay format shown below has been developed to evaluate the resistance of an immunoglobulin, pre-bound to the corresponding antigen, to surfactant induced denaturation or deformation. The relative resistance of polyclonal and monoclonal mouse anti-S.sanguis antibodies were measured.
See fig. 4
Antibody reagents were added sequentially to whole S.sanguis cells immobilized on plastic microtitre dishes, with intermediate wash steps to remove unbound antibody. Varying concentrations of nonionic surfactant or sodium dodecyl -sulphate (SDS) were added to wells containing bound anti-S.sanguis antibody and incubated for 20 minutes at approximately 20°C. After further washing, anti-mouse immunoglobulin-alkaline phosphatase conjugate was added to
detect bound antibody.
Nonionic surfactants at concentrations up to 1% (w/v) did not reverse the binding of murine monoclonal antibodies to S.sanguis cells, even though the same antibodies were dramatically affected by exposure to SDS at > 0.2% w/v.
Polyclonal anti-S.sanguis antibodies tested behaved similarly, although greater resistance to the chaotropic ' effects of SDS was observed as compared with the monoclonals.
Polyclonal anti-S.sanguis:
Detergent O.D. 410 nm Concentration % (w/v) Cremophor Synperonic SDS
0 1.593 1.601 1.743
0.02 1.575 1.627 1.767
0.05 1.545 1.667 1.772
0.1 1.532 1.668 1.442
0.2 1.614 1.803 1.16
0.5 1.617 1.692 1.159
1 1.496 1.531 0.882
2 1.513 1.724 1.013
5 1.4 1.537 0.687
10 1.45 1.555 0.626
13
Monoclonal anti-S.sanguis (IgM)
Detergent O.D. 410 nm Concentration % (w/v) Cremophor Synperonic SDS
0 1.033 1.085 1.130
0.02 1.004 1.171 1.022
0.05 0.975 1.111 1.073
0.1 0.978 1.110 0.862
0.2 1.259 1.078 0.016
0.5 1.05 1.101 0.015
1 1.074 1.197 0.015 *"*
2 1.042 1.183 0.015
5* 1.036 1.197 0.015
10 1.083 1.138 0.015
EXAMPLE 5
The stability of anti-glucose oxidase antibody was tested in the following mouthwashes:
INGREDIENT
% bv weight % by weight
Sorbitol 40.0 8.0
Glycerol - 4.0
Ethanol 15.0 6.0
Glycine 1.0 -
Synperonic F68 1.0 -
Cremophor RH40 - 0.09
Flavour oil 0.20 0.10
Colour 0.03 0.25
NaF 0.02 0.05
Saccharin - 0.03
Water 42.75 81.48 pH 6.0 6.5
A mouse monoclonal antibody against glucose oxidase was added to each mouthwash at a concentration of 60 μg MAb/ml of mouthwash. Mouthwashes were stored in closed bottles for 1 year at 28°C.
Experimental
Immunoreactivity of whole antibody against glucose oxidase was measured by enzyme linked immunosorbent assay (ELISA) in which glucose oxidase was immobilized on the surface of a nylon peg. The pegs were exposed sequentially to test paste samples containing anti-glucose oxidase .antibody, anti-mouse alkaline phosphatase enzyme immuno-conjugate, and finally to enzyme substrate, para-nitrophenylphosphate. The generation of yellow product was measured by spectrophotometry (O.D. 405 nm) .
Storage stability of anti-GOx in mouthwashes:
Time Residual immunoreactivity
Mouthwash A Mouthwash B
1 day 100 % 111 %
7 days 90 % 150 %
* 28 days 64 % 64 %
140 days 45 % 56 %
296 days 3 % 22 %
For comparison the same mouse monoclonal antibody against glucose oxidase (anti-GOx) was stored in phosphate buffered saline (PBS) pH 7.2 + 0.2 g/1 sodium azide. The composition of PBS: 8.5 g/1 NaCl + 1.07 g/1 Na2HP04 (anhydrous) + 0.39 g/1 NaH2P04.2H20. The solution was filter sterilised through a 0.22 μm Millipore filter prior to storage. The anti-GOx was added at 60 μg/ml. The solution was stored at 28°C. The residual immunoreactivity was measured with time.
Storage of anti-GOx in buffer:
Example 6
Surfactant solutions were prepared in PBS: 1. Control (PBS only)
2. 2 % SLS (Empicol LZPV/C)
3. 2 % Cremophor RH40
4. 2 % Synperonic PE/F68
All solutions were then heat sterilised. The Fv fragment of monoclonal antibody against lysozyme was added to each solution at a concentration of 10 μg Fv/ml. Solutions were stored in closed bottles at 28°C. The residual immunoreactivity was measured with time using the method given in Example 3.
Storage stability of antibody fragment Fv-lys:
Claims
1. An oral composition comprising an antibody and a surfactant, characterised in that the surfactant is or comprises a nonionic surfactant.
2. A composition according to claim 1, characterised in that the nonionic surfactant is or comprises an ethylene oxide/propylene oxide block copolymer of the general formula H-(0-CH2CH2)a-(O-CH-(CH3)CH2)b-(0- CH2CH2)a-OH in which a and b are integers greater than O, said copolymer having an average molecular weight of between 4,000 and 15,000 and having an HLB-value between 27 and 30.5 and comprising about 80 % by weight of ethylene oxide in the molecule.
3. A composition according to claim 1, characterised in that the nonionic surfactant is or comprises a hydrogenated castor oil, condensed with 40-60 moles of ethylene oxide.
4. A composition according to claims 1-3, characterised in that the antibody is an antibody against S.sanguis or against glucose oxidase or against horse radish peroxidase.
5. A composition according to claims 1-4, characterised in that the oral care composition is a toothpaste or a mouthwash.
6. Use of a nonionic surfactant as stabilizing agent in antibody-containing oral care compositions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU73450/94A AU7345094A (en) | 1993-07-01 | 1994-06-29 | Oral compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93305153 | 1993-07-01 | ||
EP93305153.4 | 1993-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995001155A1 true WO1995001155A1 (en) | 1995-01-12 |
Family
ID=8214454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/002132 WO1995001155A1 (en) | 1993-07-01 | 1994-06-29 | Oral compositions |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7345094A (en) |
WO (1) | WO1995001155A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5709852A (en) * | 1995-12-05 | 1998-01-20 | Basf Corporation | Ethylene oxide/propylene oxide/ethylene oxide (EO/PO/EO) triblock copolymer carrier blends |
WO1998044948A2 (en) * | 1997-04-07 | 1998-10-15 | Cangene Corporation | Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties |
US5919830A (en) * | 1998-04-30 | 1999-07-06 | Gopalkrishnan; Sridhar | Stable non-aqueous blends for personal care compositions |
GB2335596A (en) * | 1998-03-24 | 1999-09-29 | Procter & Gamble | Polyalkyleneglycol Copolymers as Lipase Inhibitors |
WO2003100420A2 (en) * | 2002-05-29 | 2003-12-04 | Kist-Europe Forschungsgesellschaft Mbh | Electrochemical enzyme immunoassay for simultaneously detecting a number of analytes |
US7087243B2 (en) * | 1997-09-09 | 2006-08-08 | Edgren David E | Pharmaceutical coating composition and method of use |
US7101889B2 (en) | 2002-02-19 | 2006-09-05 | The Procter & Gamble | Lipase inhibiting composition |
US7419659B2 (en) | 2001-12-05 | 2008-09-02 | Ucb Pharma S.A. | Expression control using variable intergenic sequences |
US8673271B2 (en) * | 2001-12-25 | 2014-03-18 | Kao Corporation | Compositions for mouth containing an anionic surfactant having reduced astringency |
US8802095B2 (en) | 2007-01-26 | 2014-08-12 | Durect Corporation | Injectable, non-aqueous suspension with high concentration of therapeutic agent |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61112028A (en) * | 1984-11-06 | 1986-05-30 | Lion Corp | Preventive for dental caries |
GB2176400A (en) * | 1985-06-14 | 1986-12-31 | Lion Corp | Oral composition |
JPS62417A (en) * | 1985-06-25 | 1987-01-06 | Lion Corp | Composition for oral cavity application |
-
1994
- 1994-06-29 AU AU73450/94A patent/AU7345094A/en not_active Withdrawn
- 1994-06-29 WO PCT/EP1994/002132 patent/WO1995001155A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61112028A (en) * | 1984-11-06 | 1986-05-30 | Lion Corp | Preventive for dental caries |
GB2176400A (en) * | 1985-06-14 | 1986-12-31 | Lion Corp | Oral composition |
JPS62417A (en) * | 1985-06-25 | 1987-01-06 | Lion Corp | Composition for oral cavity application |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Week 8706, Derwent World Patents Index; AN 87-040921 (06) * |
PATENT ABSTRACTS OF JAPAN vol. 010, no. 296 (C - 377) 8 October 1986 (1986-10-08) * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5709852A (en) * | 1995-12-05 | 1998-01-20 | Basf Corporation | Ethylene oxide/propylene oxide/ethylene oxide (EO/PO/EO) triblock copolymer carrier blends |
WO1998044948A2 (en) * | 1997-04-07 | 1998-10-15 | Cangene Corporation | Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties |
WO1998044948A3 (en) * | 1997-04-07 | 1999-02-11 | Cangene Corp | Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties |
US7087243B2 (en) * | 1997-09-09 | 2006-08-08 | Edgren David E | Pharmaceutical coating composition and method of use |
GB2335596A (en) * | 1998-03-24 | 1999-09-29 | Procter & Gamble | Polyalkyleneglycol Copolymers as Lipase Inhibitors |
US5919830A (en) * | 1998-04-30 | 1999-07-06 | Gopalkrishnan; Sridhar | Stable non-aqueous blends for personal care compositions |
US7419659B2 (en) | 2001-12-05 | 2008-09-02 | Ucb Pharma S.A. | Expression control using variable intergenic sequences |
US8673271B2 (en) * | 2001-12-25 | 2014-03-18 | Kao Corporation | Compositions for mouth containing an anionic surfactant having reduced astringency |
US7101889B2 (en) | 2002-02-19 | 2006-09-05 | The Procter & Gamble | Lipase inhibiting composition |
WO2003100420A2 (en) * | 2002-05-29 | 2003-12-04 | Kist-Europe Forschungsgesellschaft Mbh | Electrochemical enzyme immunoassay for simultaneously detecting a number of analytes |
WO2003100420A3 (en) * | 2002-05-29 | 2004-04-01 | Kist Europe Forschungsges Mbh | Electrochemical enzyme immunoassay for simultaneously detecting a number of analytes |
US8802095B2 (en) | 2007-01-26 | 2014-08-12 | Durect Corporation | Injectable, non-aqueous suspension with high concentration of therapeutic agent |
Also Published As
Publication number | Publication date |
---|---|
AU7345094A (en) | 1995-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5801226A (en) | Oral care compositions | |
US5824292A (en) | Oral care compositions | |
AU630028B2 (en) | Antibacterial antiplaque anticalculus oral composition | |
US7939306B2 (en) | Antibacterial dentifrice exhibiting antiplaque and breath freshening properties | |
AU703912B2 (en) | Antimicrobial oral composition | |
EP1203575B1 (en) | Clear gel-type dentrifices | |
EP0697861B1 (en) | Oral compositions containing triclosan for the treatment of aphthous ulcers | |
WO1995001155A1 (en) | Oral compositions | |
WO1995001154A1 (en) | Oral care compositions | |
EP1171085B1 (en) | Oral care composition | |
US6436371B2 (en) | Oral composition | |
US20030191209A1 (en) | Dental compositions | |
EP0659068B1 (en) | Mouth-care products with anti-bacterial activity | |
EP0737470A1 (en) | Oral care compositions | |
US20030077232A1 (en) | Composition | |
US5069896A (en) | Malodor inhibiting skin deodorant composition comprising a monoclonal antibody and method of deodorizing | |
EP1282392B1 (en) | Oral composition | |
JPH0699292B2 (en) | Oral composition | |
US20030068282A1 (en) | Composition | |
EP0868167B1 (en) | Desensitising toothpaste | |
EP1284713B1 (en) | Oral composition comprising chalk | |
WO1995001173A1 (en) | Amphoteric surfactant for the treatment of aphthous ulcers | |
JPH11505819A (en) | Herring-containing composition | |
Do et al. | A STUDY ON THE CHANGES OF THE ROOT SURFACE PLAQUE FLORA AND GINGIVAL CREVICULAR FLUID ANTIBODY TITERS AFTER ANTIMICROBIAL VARNISH TREATMENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WA | Withdrawal of international application | ||
122 | Ep: pct application non-entry in european phase | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |